SEC Form 13F Information Table Summary
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Carlyle Group Inc. for the reporting period ending December 31, 2023. The document discloses the investment manager's holdings in equity securities as required by the Securities and Exchange Commission. It does not contain Carlyle Group's own financial performance data (revenue, profit, or cash flow) but rather details the specific portfolio positions managed by the firm.
Key Financial Metrics and Portfolio Composition
The filing lists 24 equity positions with a combined reported value of approximately $1.3 billion (sum of Column 5 values). The portfolio is heavily weighted toward biotechnology, healthcare, and technology sectors. Voting authority is primarily held solely by the investment manager.
| Issuer | Class | Value (USD) | Shares/Units | Voting Authority |
|---|---|---|---|---|
| ZoomInfo Technologies Inc | Common Stock | $651,670,324 | 35,244,474 | Sole |
| Quidelortho Corp | Common Stock | $918,315,487 | 12,460,183 | Sole |
| Soleno Therapeutics Inc | Common Stock | $115,038,749 | 2,857,804 | Sole |
| Vitru Ltd | Common Stock | $98,444,383 | 6,246,471 | Sole |
| Getty Images Holdings Inc | Class A Common | $49,320,175 | 9,394,319 | Sole |
| Verona Pharma Plc | Sponsored ADR | $48,805,950 | 2,457,500 | Sole |
| GDS Hldgs Ltd | Sponsored ADS | $37,142,334 | 4,072,624 | Sole |
| Phathom Pharmaceuticals Inc | Common Stock | $31,925,857 | 3,496,808 | Sole |
| Hillevax Inc | Common Stock | $29,507,700 | 1,838,486 | Sole |
| Smart Sh Global Ltd | ADS | $2,409,914 | 4,810,209 | Sole |
Note: The table above lists the top 10 holdings by value. The filing includes 14 additional positions, including Adicet Bio, Effector Therapeutics, and CubeSmart.
Material Changes and Guidance
Material Changes: This filing is a snapshot of holdings as of the period end. It does not provide comparative data against the prior quarter (September 30, 2023) within this text, so specific changes in position size or new entries cannot be quantified without the prior filing.
Guidance and Outlook: Form 13F filings do not contain management commentary, forward-looking guidance, or risk factors regarding the investment manager's future strategy. The filing strictly reports historical ownership data.
Investor Verification Checklist
- Portfolio Concentration: Verify the impact of the two largest holdings (ZoomInfo and Quidelortho), which represent a significant portion of the disclosed equity value.
- Sector Exposure: Confirm the firm's heavy exposure to the biotechnology and life sciences sector (e.g., Soleno, Phathom, Jasper, Vera Therapeutics).
- Voting Rights: Note that for all listed positions, the investment manager holds "Sole" voting authority, indicating direct control over voting decisions for these shares.
- Valuation Basis: Understand that the "Value" column reflects the market value at the end of the reporting period (Dec 31, 2023) and may differ from current market prices.
- Missing Data: Acknowledge that this document does not disclose Carlyle Group's own financial health, debt levels, or cash flow.